Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 8 minute read Pharma Industry News United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF United Therapeutics reports strong Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis. Discover why this inhaled therapy could reshape treatment. byVenkateshMarch 12, 2026